Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, has signed a multi-year contract with Elsevier, which will provide unlimited Reaxys access to all Pharmaron researchers. Reaxys will enable Pharmaron to continue to consolidate its scientific excellence and to stay competitive in drug R&D, and also ensure that Pharmaron has the best possible resources available to provide high-quality research and solutions to their customers.
"Our partners depend on the high-quality drug R&D services that we provide. The information our scientists have access to is a critical componentof our drug R&D services," said Dr. Tongqian Chen, Senior Vice President of Chemistry at Pharmaron. "Reaxys' proven track record in providing an unparalleled quality of information will allow our scientists in the labs to plan and execute in a more productive manner. We are delighted to have Elsevier as our scientific information providing partner and look forward to the productive collaboration."
Pharmaron is a key player in the Chinese CRO industry, a preferred drug R&D service provider to global pharmaceutical and chemical companies. The increased emphasis on partnership and productivity has made validated information access indispensible. Consequently access to Reaxys' chemical information will be a significant aspect in helping Pharmaron continue to be a highly competitive and dynamic player in the industry.
"Reaxys provides the relevant information that enables researchers to work effectively; we are committed to ensuring that researchers can immediately take their findings from Reaxys and apply them effectively in the lab," said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. "We look forward to continuing to support Pharmaron's ongoing R&D work."
Study highlights growing burden of neurological disorders worldwide